NASDAQ:GELS Gelteq (GELS) Stock Price, News & Analysis $0.28 +0.01 (+3.93%) Closing price 11/19/2026 03:59 PM EasternExtended Trading$0.28 0.00 (-0.57%) As of 11/19/2026 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsSEC Filings About Gelteq Stock (NASDAQ:GELS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Gelteq alerts:Sign Up Key Stats Today's Range$0.28▼$0.3050-Day Range$0.27▼$0.7052-Week Range$0.26▼$2.01Volume10,956 shsAverage Volume74,865 shsMarket Capitalization$3.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Gelteq is an Australian food-technology company that develops gel-based delivery systems for ingredients used in human and animal health products. Its platform is designed to incorporate active ingredients into gels as an alternative format to conventional tablets, capsules, powders and liquids. The company’s applications include nutraceuticals and dietary supplements, pharmaceutical products, and animal-health and nutrition products. Gelteq works with businesses seeking to develop or manufacture products using its gel technology.AI Generated. May Contain Errors. Read More Gelteq Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreGELS MarketRank™: 0.92029185022 of 5 starsGelteq scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingGelteq has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageGelteq has only been the subject of 1 research reports in the past 90 days.Read more about Gelteq's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioGelteq has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.13% of the float of Gelteq has been sold short.Short Interest Ratio / Days to CoverGelteq has a short interest ratio ("days to cover") of 2.08, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Gelteq has recently decreased by 27.48%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGelteq does not currently pay a dividend.Dividend GrowthGelteq does not have a long track record of dividend growth. News and Social Media1.4 / 5News Sentiment0.31 News SentimentGelteq has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Gelteq this week, compared to 2 articles on an average week. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Gelteq insiders have not sold or bought any company stock.Percentage Held by InstitutionsGelteq has minimal institutional ownership at this time.Read more about Gelteq's insider trading history. Receive GELS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gelteq and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GELS Stock News HeadlinesGelteq Limited Reports Earnings Results for the Full Year Ended June 30, 2026November 17 at 9:34 AM | marketscreener.comMGelteq Limited Reports Delay in Annual FilingNovember 2, 2026 | tipranks.comBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvidia's. A NASA scientist says the technology behind it is bigger than AI. Musk calls it "Amazing," and a Nobel Prize winner describes its power as "unprecedented in the history of life on Earth." Adam O'Dell, Chief Investment Strategist at Money and Markets, names the company at the center of it all. | Banyan Hill Publishing (Ad)Could Gelteq’s (GELS) Gel Improve Oral Drug Delivery?October 9, 2026 | finance.yahoo.comGelteq Appoints Dr. Paul Wynne as Chief Scientific Officer to Propel Innovative Ingestible Gel TechnologyJuly 2, 2026 | stockhouse.comGelteq Limited Advances Clinical Programs and Asia Expansion in First Half of 2026June 30, 2026 | tipranks.comGelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple ProgramsJune 17, 2026 | globenewswire.comGelteq Limited: Gelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq Technology for Animal Health ApplicationsJune 13, 2026 | finanznachrichten.deSee More Headlines GELS Stock Analysis - Frequently Asked Questions How have GELS shares performed this year? Gelteq's stock was trading at $0.80 at the start of the year. Since then, GELS shares have decreased by 64.9% and is now trading at $0.2806. How were Gelteq's earnings last quarter? Gelteq Limited (NASDAQ:GELS) posted its earnings results on Monday, November, 16th. The company reported ($0.64) earnings per share (EPS) for the quarter. When did Gelteq IPO? Gelteq (GELS) raised $5 million in an initial public offering (IPO) on Tuesday, October 29th 2024. The company issued 1,300,000 shares at $4.00 per share. The Benchmark Company acted as the underwriter for the IPO. How do I buy shares of Gelteq? Shares of GELS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/16/2026Today11/19/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 GELS's financial health is in the Yellow zone, according to TradeSmith. GELS has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:GELS Previous SymbolNASDAQ:GELS CIK1920092 Webwww.gelteq.com Phone61-3-9087-3990FaxN/AEmployees18Year Founded2018Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$240 thousand Price / Sales13.46 Cash FlowN/A Price / Cash FlowN/A Book Value$1.08 per share Price / Book0.26Miscellaneous Outstanding Shares11,510,000Free FloatN/AMarket Cap$3.23 million OptionableN/A Beta-0.37 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:GELS) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gelteq Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Gelteq With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.